EMA reviewing psoriasis candidate from Sun, Almirall

Almirall S.A. (Madrid:ALM) and Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA) said EMA validated an MAA for tildrakizumab (MK-3222), their mAb against IL-23, to treat moderate to severe plaque psoriasis.

Almirall has the candidate's rights in Europe to treat psoriasis. Sun has worldwide, ex-European rights to tildrakizumab from Merck & Co. Inc. (NYSE:MRK). In the company's earnings update in February, Sun said it expects Merck to submit a BLA to FDA during Sun's FY18, which is to begin April 1...